Calprotectin As New Potential Clinical Marker for Multiple Myeloma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Mar 17

PMID 36928900

Authors

Parisa Khosravi

Saeid Abroun

Saeid Kaviani

Saman Masoudifar

Homayoun Sarough Farahani

Affiliations

Soon will be listed here.

Abstract

Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in μg/g of feces. Values above 50 μg/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.

Citing Articles

Do Alarmins Have a Role in Multiple Myeloma?.

Geduk A, Polat M, Terzi Demirsoy E, Oztas B, Eryilmaz B, Yenihayat E Turk J Haematol. 2024; 41(2):83-90.

PMID: 38426298 PMC: 11589251. DOI: 10.4274/tjh.galenos.2024.2023.0469.

References

Volkers M, Rohde D, Goodman C, Most P . S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol. 2010; 2010:178614. PMC: 2846685. DOI: 10.1155/2010/178614. View

Nakashige T, Zygiel E, Drennan C, Nolan E . Nickel Sequestration by the Host-Defense Protein Human Calprotectin. J Am Chem Soc. 2017; 139(26):8828-8836. PMC: 5754018. DOI: 10.1021/jacs.7b01212. View

Vijayvargiya P, Gonsalves W, Burton D, Hogan W, Miceli T, Rossini W . Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. Bone Marrow Transplant. 2019; 54(11):1898-1907. DOI: 10.1038/s41409-019-0581-6. View

Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C . Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?. Front Oncol. 2020; 10:189. PMC: 7057289. DOI: 10.3389/fonc.2020.00189. View

Yatime L, Betzer C, Jensen R, Mortensen S, Jensen P, Andersen G . The Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for S100 Proteins. Structure. 2016; 24(12):2043-2052. DOI: 10.1016/j.str.2016.09.011. View

Ricciuto A, Griffiths A . Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci. 2019; 56(5):307-320. DOI: 10.1080/10408363.2019.1619159. View

Bohnhorst J, Rasmussen T, Moen S, Flottum M, Knudsen L, Borset M . Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006; 20(6):1138-44. DOI: 10.1038/sj.leu.2404225. View

Gonzalez Jimenez D, Rodriguez-Belvis M, Ortega G, Segarra Canton O, Diaz Martin J . Faecal calprotectin in children with multisystem inflammatory syndrome: A pilot case-control study. Acta Paediatr. 2021; 110(7):2246-2248. DOI: 10.1111/apa.15856. View

Mantovani A, Garlanda C . Inflammation and multiple myeloma: the Toll connection. Leukemia. 2006; 20(6):937-8. DOI: 10.1038/sj.leu.2404229. View

10.

Harmer D, Falank C, Reagan M . Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne). 2019; 9:788. PMC: 6333051. DOI: 10.3389/fendo.2018.00788. View

11.

Buisson A, Mak W, Andersen M, Lei D, Kahn S, Pekow J . Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019; 13(8):1012-1024. PMC: 6939876. DOI: 10.1093/ecco-jcc/jjz023. View

12.

Ayling R, Kok K . Fecal Calprotectin. Adv Clin Chem. 2018; 87:161-190. DOI: 10.1016/bs.acc.2018.07.005. View

13.

Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I . Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001; 49(3):402-8. PMC: 1728420. DOI: 10.1136/gut.49.3.402. View

14.

Mumolo M, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E . From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018; 24(33):3681-3694. PMC: 6127662. DOI: 10.3748/wjg.v24.i33.3681. View

15.

Lehmann F, Trapani F, Fueglistaler I, Terracciano L, von Flue M, Cathomas G . Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World J Gastroenterol. 2014; 20(17):4994-9. PMC: 4009532. DOI: 10.3748/wjg.v20.i17.4994. View

16.

Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo L, Mann H . Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clin Rheumatol. 2018; 37(8):2055-2062. DOI: 10.1007/s10067-018-4091-5. View

17.

Soare I, Sirbu A, Diculescu M, Mateescu B, Tieranu C, Martin S . Lean mass, magnesium, faecal calprotectin and glucocorticoid exposure as risk factors for low bone mineral density in inflammatory bowel disease patients. Endocr Connect. 2021; 10(8):918-925. PMC: 8428027. DOI: 10.1530/EC-21-0138. View

18.

Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M . Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020; 510:556-565. PMC: 7431395. DOI: 10.1016/j.cca.2020.08.025. View

19.

Shabani F, Farasat A, Mahdavi M, Gheibi N . Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018; 67(10):801-812. DOI: 10.1007/s00011-018-1173-4. View

20.

Ehrchen J, Sunderkotter C, Foell D, Vogl T, Roth J . The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009; 86(3):557-66. DOI: 10.1189/jlb.1008647. View